INTERCEPT Plasma: Journal Articles

  1. JP Cazenave, C Waller, D Kientz, I Mendel, L Lin, M Jacquet, M Propst, W Liu, L Corash, D Sundin, L Defoin, N Messe, and JCOsselaer. An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment. Transfusion. 2010 Jan. [Epub ahead of print]
    > View abstract


  2. J Irsch, L Pinkoski, L Corash, L Lin.  INTERCEPT plasma: comparability with conventional fresh-frozen plasma based on coagulation function – an in vitro analysis. Vox Sanguinis 2010: 98, 47–55
    > View abstract
  3. N de Valensart, A Rapaille, E Goossenaerts, D Sondag-Thull, V Deneys. Study of coagulation function in thawed apheresis plasma for photochemical treatment by amotosalen and UVA. Vox Sang. 2009;96:213-218.
    > View abstract
  4. JC Osselaer, C Debry, M Goffaux, et al. Coagulation function in fresh frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen. Transfusion 2008 Jan;48(1):108-17.
    > View abstract
  5. J Cid, L Ramiro, N Martínez, M Palomo, O Magallon, M Claparols, P Ortiz, L Puig, RP Pla. Quantitative and Qualitative Analysis of Proteins in Fresh Frozen Plasma Obtained from Whole Blood Donations and Prepared with Two Photochemical Treatments. Transfus Apher Sci. 2008 Oct;39(2):115-21.
    > View abstract
  6. P Grellier, J Benach, M Labaied, S Charneau, H Gil, G Monsalve, R Alfonso, L Sawyer, L Lin, M Steiert, K Dupuis. Photochemical Inactivation with Amotosalen and Long-Wavelength Ultraviolet Light of Plasmodium and Babesia in Platelet and Plasma Components. Transfusion 2008 Aug;48(8):1676-84.
    > View abstract
  7. P Schlenke, T Hervig, H Isola, ML Wiesel, et al. Photochemical Treatment of Plasma with Amotosalen and UVA Light: Process Validation in Three European Blood Centers. Transfusion 2008 Apr;48(4):697-705.
    > View abstract
  8. HJ Alter. Pathogen Reduction: a Precautionary Principle Paradigm. Transfus Med Rev 2008 Apr;22(2):97-102.
    > View abstract
  9. Y Singh, LS Sawyer, LS Pinkoski, et al. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 2006;46:1168-77
  10. PD Mintz, NM Bass, LD Petz, et al. Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. Blood 2006;107:3753-60
  11. Mintz PD, Neff A, MacKenzie M, et al. A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 2006;46:1693-704
  12. V Jauvin, RD Alfonso, B Guillemain, K Dupuis and HJ Fleury. In vitro photochemical inactivation of cell-associated human T-cell leukemia virus Type I and II in human platelet concentrates and plasma by use of amotosalen. Transfusion 2005;45:1151-9
  13. L Lin, MG Conlan, J Tessman, G Cimino and S Porter. Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment. Transfusion 2005;45:1610-20
  14. P de Alarcon, R Benjamin, M Dugdale, et al. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies. Transfusion 2005;45:1362-72
  15. JP Allain, C Bianco, MA Blajchman, et al. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfus Med Rev 2005;19:110-26
  16. L Corash, L Lin. Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease. Bone Marrow Transplant 2004;33:1-7
  17. P Schlenke. Protection against Transfusion-Associated Graft-versus-Host Disease in Blood Transfusion: Is Gamma-Irradiation the Only Answer? Transfusion Med Hemo. 2004;31:24-31
  18. L Corash. Pathogen reduction technology: methods, status of clinical trials, and future prospects. Curr Hematol Rep 2003;2:495-502
  19. WC Van Voorhis, LK Barrett, RT Eastman, R Alfonso and K Dupuis. Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV. Antimicrob Agents Chemother 2003;47:475-9
  20. J Hambleton, D Wages, L Radu-Radulescu, et al. Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion 2002;42:1302-7
  21. S Wollowitz. Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. Semin Hematol 2001;38:4-11

 

 
© Cerus Corporation. All Rights Reserved.

Use of the INTERCEPT Blood System in the United States is limited by Federal law to investigational use. If you are a resident of the U.S., please click here.

The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located. The INTERCEPT Blood System is CE marked for use with platelets and plasma. No pathogen inactivation system has been shown to inactivate all pathogens.

Website design by NetPilot Web Solutions
Legal Info  |   Privacy Policy